Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000754
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a IFN Alfa-2a in Combination With Zidovudine AZT and Dideoxycytidine ddC Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cellsmm3
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Organization Data
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Class:
NIH
Study ID:
ACTG 197
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Glaxo Wellcome | INDUSTRY |
| Hoffmann-La Roche | INDUSTRY |